Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Launched by UNIVERSITY OF AARHUS · Mar 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a new test that looks for circulating tumor DNA (ctDNA) in the blood can help doctors better diagnose ovarian cancer. Specifically, the researchers want to see if measuring ctDNA can improve the ability to tell the difference between benign (non-cancerous) and malignant (cancerous) ovarian masses before surgery. They will also explore how ctDNA results work alongside imaging tests like ultrasounds and MRIs, as well as a blood marker called CA 125, to create a better diagnostic plan.

To participate in this trial, women aged 65 to 74 who are suspected of having an ovarian tumor can apply. It's important that participants can give informed consent, meaning they understand the study and agree to join. Those who have previously been diagnosed with ovarian cancer are not eligible. If you join the study, you will provide blood and tissue samples and have your medical imaging results collected to help researchers learn more about ovarian cancer and improve diagnosis methods in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Suspected ovarian neoplasm
• • Informed consent
• Exclusion Criteria:
• • Inability to give informed consent
• • Previous ovarian cancer diagnosis